ArticleThe Journal of infectious diseases2019
Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Doxycycline host-directed therapy in human pulmonary tuberculosis.The Journal of clinical investigation · 2021Trial
- Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances.Infection and immunity · 2026Review
- Host-Directed Therapies Based on Protease Inhibitors to ControlMicroorganisms · 2025Review
- Host-directed therapy for tuberculosis.European journal of medical research · 2025Review
- Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium.American journal of respiratory and critical care medicine · 2024Review
- Review
- IL-10 Modulation Increases Pyrazinamide's Antimycobacterial Efficacy against Mycobacterium tuberculosis Infection in Mice.ImmunoHorizons · 2023Article
- PET/CT imaging of CSF1R in a mouse model of tuberculosis.European journal of nuclear medicine and molecular imaging · 2022Article
- Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy.PLoS pathogens · 2022Article
- Understanding the tuberculosis granuloma: the matrix revolutions.Trends in molecular medicine · 2022Review
- Remodeling the matrix: doxycycline modulates tuberculosis immunopathology.The Journal of clinical investigation · 2021Article
- Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets.The Journal of clinical investigation · 2021Article
- Host-directed therapy to combat mycobacterial infections.Immunological reviews · 2021Review
- Visualizing the dynamics of tuberculosis pathology using molecular imaging.The Journal of clinical investigation · 2021Review
- The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis.Antioxidants & redox signaling · 2021Review
- Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.Frontiers in immunology · 2021Review
- Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.Frontiers in immunology · 2021Review
- Cavitary tuberculosis: the gateway of disease transmission.The Lancet. Infectious diseases · 2020Review
- Radiosynthesis and Biodistribution ofACS infectious diseases · 2020Article
- Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis.Cell proliferation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Matrix metalloproteinases (MMPs) degrade extracellular matrix and are implicated in tuberculosis pathogenesis and cavitation. In particular, MMP-7 is induced by hypoxia and highly expressed around pulmonary cavities of Mycobacterium tuberculosis-infected C3HeB/FeJ mice. In this study, we evaluated whether administration of cipemastat, an orally available potent inhibitor of MMP-7, could reduce pulmonary cavitation in M. tuberculosis-infected C3HeB/FeJ mice. We demonstrate that, compared with untreated controls, cipemastat treatment paradoxically increases the frequency of cavitation (32% vs 7%; P = .029), immunopathology, and mortality. Further studies are needed to understand the role of MMP inhibitors as adjunctive treatments for pulmonary tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.